← Eichor
Study identifier: NCT06479135 Synced from ClinicalTrials.gov · July 29, 2026
● Recruiting

Study of Navtemadlin add-on to Ruxolitinib in JAK Inhibitor-Naïve Patients With Myelofibrosis Who Have a Suboptimal Response to Ruxolitinib

Condition: Myelofibrosis · Post-PV MF · Post-ET Myelofibrosis  ·  Sponsor: Kartos Therapeutics, Inc.

PhasePhase 3
Planned participants600
Who can joinAll sexes, 18 Years to no upper limit
Healthy volunteersNo

About this study

This clinical trial is evaluating whether addition of navtemadlin to ruxolitinib treatment will provide more clinical benefit than ruxolitinib alone for patients with Myelofibrosis who have a suboptimal response to ruxolitinib treatment alone. Subjects will start by receiving ruxolitinib alone in the run-in period. Those who demostrate a suboptimal response from ruxolitinib alone will then be randomized 2:1 to receive navtemadlin or navtemadlin placebo as add-on treatment to their ongoing ruxolitinib. Randomized means that subjects will be assigned to a group by chance, like a flip of a coin. The study is blinded, meaning the subjects, doctors, central endpoint assessors and sponsor will not know which add on treatment (navtemadlin or navtemadlin placebo) the subject is receiving.

This description comes directly from the study's public registry record.

Talk to the study team

John Mei  ·  650-542-0136  ·  jmei@kartosthera.com

Always discuss trial participation with your own doctor first.

Locations (215)

UAB HospitalBirmingham, Alabama, United StatesRecruiting
Banner MD Anderson Cancer CenterGilbert, Arizona, United StatesRecruiting
Mayo Clinic - PhoenixPhoenix, Arizona, United StatesRecruiting
UC San Diego Moores Cancer CenterLa Jolla, California, United StatesRecruiting
UCLA Hematology/Oncology Clinic - Los AngelesLos Angeles, California, United StatesRecruiting
Scripps Health, Prebys Cancer CenterSan Diego, California, United StatesRecruiting
The Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical CenterTorrance, California, United StatesRecruiting
Rocky Mountain Cancer Centers - AuroraAurora, Colorado, United StatesRecruiting
Medical Oncology Hematology Consultants, PANewark, Delaware, United StatesRecruiting
MedStar Georgetown University Hospital, Lombardi Comprehensive Cancer CenterWashington D.C., District of Columbia, United StatesRecruiting
Mayo Clinic - JacksonvilleJacksonville, Florida, United StatesRecruiting
University of MiamiMiami, Florida, United StatesRecruiting

+ 203 more locations — full list on the registry record.

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT06479135